Predicting benefit from anti-angiogenic agents in malignancy

Nat Rev Cancer. 2006 Aug;6(8):626-35. doi: 10.1038/nrc1946. Epub 2006 Jul 13.


A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Predictive Value of Tests
  • Treatment Outcome


  • Angiogenesis Inhibitors
  • Biomarkers, Tumor